Christina S Meade1, Sheri L Towe2, Linda M Skalski3, Kevin R Robertson4. 1. Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences and Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. Electronic address: christina.meade@duke.edu. 2. Duke University School of Medicine, Department of Psychiatry and Behavioral Sciences and Duke Global Health Institute, Box 90519, Durham, NC 27708, USA. 3. Duke University, Department of Psychology and Neuroscience, Box 90086, Durham, NC 27708, USA. 4. University of North Carolina at Chapel Hill, Department of Neurology, Physicians Office Building, 170 Manning Drive, Chapel Hill, NC 27599, USA.
Abstract
BACKGROUND: Prior studies have established that methamphetamine and HIV can have additive deleterious effects on neurocognitive functioning, but there has been relatively little research on other stimulants like cocaine. This study investigated the effects of cocaine and HIV on neurocognitive impairment in a large, well-characterized sample. METHODS: The sample included 193 adults across four groups: HIV-positive cocaine users (n = 48), HIV-negative cocaine users (n = 53), HIV-positive non-drug users (n = 60), and HIV-negative non-drug users (n = 32). Cocaine users met criteria for lifetime dependence and had past-month cocaine use. A comprehensive battery assessed substance abuse and neurocognitive functioning. RESULTS: Participants were mostly male (66%) and African-American (85%), with a mean age of 46.09 years. The rate of global impairment was 33%, with no significant main effects across groups on likelihood of impairment. There were main effects for cocaine on processing speed and executive functioning, with cocaine users having greater impairment (F = 9.33 and F = 4.22, respectively), and for HIV on attention, with HIV-infected persons having greater impairment (F = 5.55). There was an interaction effect for executive functioning, with the three patient groups having greater impairment than controls (F = 5.05). Nonparametric analyses revealed significant additive impairment in the presence of both HIV and cocaine for processing speed. CONCLUSIONS: While cocaine does not appear to increase vulnerability to global HIV-associated neurocognitive impairment, it does have independent adverse effects on executive functioning and processing speed. Given prior evidence that domain-specific deficits predict real-world impairments, our results may help explain the poorer behavioral and functional outcomes observed in HIV-infected cocaine users.
BACKGROUND: Prior studies have established that methamphetamine and HIV can have additive deleterious effects on neurocognitive functioning, but there has been relatively little research on other stimulants like cocaine. This study investigated the effects of cocaine and HIV on neurocognitive impairment in a large, well-characterized sample. METHODS: The sample included 193 adults across four groups: HIV-positive cocaine users (n = 48), HIV-negative cocaine users (n = 53), HIV-positive non-drug users (n = 60), and HIV-negative non-drug users (n = 32). Cocaine users met criteria for lifetime dependence and had past-month cocaine use. A comprehensive battery assessed substance abuse and neurocognitive functioning. RESULTS:Participants were mostly male (66%) and African-American (85%), with a mean age of 46.09 years. The rate of global impairment was 33%, with no significant main effects across groups on likelihood of impairment. There were main effects for cocaine on processing speed and executive functioning, with cocaine users having greater impairment (F = 9.33 and F = 4.22, respectively), and for HIV on attention, with HIV-infectedpersons having greater impairment (F = 5.55). There was an interaction effect for executive functioning, with the three patient groups having greater impairment than controls (F = 5.05). Nonparametric analyses revealed significant additive impairment in the presence of both HIV and cocaine for processing speed. CONCLUSIONS: While cocaine does not appear to increase vulnerability to global HIV-associated neurocognitive impairment, it does have independent adverse effects on executive functioning and processing speed. Given prior evidence that domain-specific deficits predict real-world impairments, our results may help explain the poorer behavioral and functional outcomes observed in HIV-infectedcocaine users.
Authors: Michael C Diehr; Mariana Cherner; Tanya J Wolfson; S Walden Miller; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2003-06 Impact factor: 2.475
Authors: J M Foley; A L Gooding; A D Thames; M L Ettenhofer; M S Kim; S A Castellon; T D Marcotte; J R Sadek; R K Heaton; W G van Gorp; C H Hinkin Journal: Am J Alzheimers Dis Other Demen Date: 2013-01-11 Impact factor: 2.035
Authors: Desirée B Spronk; Janelle H P van Wel; Johannes G Ramaekers; Robbert J Verkes Journal: Neurosci Biobehav Rev Date: 2013-07-20 Impact factor: 8.989
Authors: Theresa Winhusen; Daniel Lewis; Bryon Adinoff; Gregory Brigham; Frankie Kropp; Dennis M Donovan; Cindy L Seamans; Candace C Hodgkins; Jessica C Dicenzo; Christopher L Botero; Davina R Jones; Eugene Somoza Journal: J Subst Abuse Treat Date: 2013-01-08
Authors: Andréa L Hobkirk; Ryan P Bell; Amanda V Utevsky; Scott Huettel; Christina S Meade Journal: Drug Alcohol Depend Date: 2018-10-24 Impact factor: 4.492
Authors: Roman Shrestha; Frederick L Altice; Brian Sibilio; Jude Ssenyonjo; Michael M Copenhaver Journal: Contemp Clin Trials Date: 2019-06-20 Impact factor: 2.226
Authors: Christina S Meade; Daniella M Cordero; Andrea L Hobkirk; Brandon M Metra; Nan-Kuei Chen; Scott A Huettel Journal: Hum Brain Mapp Date: 2016-03-23 Impact factor: 5.038
Authors: Tina M Calderon; Dionna W Williams; Lillie Lopez; Eliseo A Eugenin; Laura Cheney; Peter J Gaskill; Mike Veenstra; Kathryn Anastos; Susan Morgello; Joan W Berman Journal: J Neuroimmune Pharmacol Date: 2017-01-29 Impact factor: 4.147
Authors: Michael K Keutmann; Raul Gonzalez; Pauline M Maki; Leah H Rubin; Jasmin Vassileva; Eileen M Martin Journal: J Clin Exp Neuropsychol Date: 2016-11-13 Impact factor: 2.475